Genomic Medicine Potentials For Cancer Therapy
- سال انتشار: 1395
- محل انتشار: دومین سمپوزیوم بین المللی سرطان نسترن
- کد COI اختصاصی: NASTARANCANSER02_186
- زبان مقاله: انگلیسی
- تعداد مشاهده: 458
نویسندگان
Department Of Pharmacy, International Branch, Shiraz University Of Medical Sciences, Shiraz, Iran
Pharmaceutical Sciences Research Center, School Of Pharmacy, Shiraz University Of Medical Sciences, Shiraz, Iran
چکیده
Nowadays, the personalized medicine, the prescription of a particular and selective therapeuticapproach best suitable for an individual, has attained a worldwide attention. Current insightsobtained from the newly emerged molecular and omics sciences has opened new avenues frompersonalized medicine approach towards individualization of the cancer therapies. Cancer genomicanalysis indicate its heritable and multi-gene basis which lead to genetic alterations and somaticmutations. Personalized medicine in commencing to play a crucial role for cancer diagnosis,prognosis, prediction of risks and treatment with more effectiveness and robustness, with lessunwanted effects on the patients and minimum cost of care. Published literature identificationthrough systematic search in pubmed, scopus and google scholar (from 1990 to 2016) sing the searchterms Personalized medicine , Cancer therapy , Cancer genomics , Oncology , Omicstechnologies and Systems medicine . The results of some molecular studies on cancer hadrevealed a great and serious role of genetic variety for different classes of cancer that appear with asame molecular pathology. Moreover, there is a rising concerns towards genetic diversity occurringin a single tumor and tumor heterogeneity. Exploitation of the cancer genomics approach has shedlight on better understanding the cancer pathology and its clinical therapy. Trastuzumab, amonoclonal antibody interfering with HER2/neu receptor has been extensively employed to treatcertain types of breast cancer. This therapeutic approach will be successful only in individuals withover expression of the HER2/neu receptor. Moreover, Imatinib, a tyrosine kinase inhibitor hasadministered for treatment of chronic myeloid leukemia (CML) in patients with a reciprocaltranslocation between chromosomes 9 and 22. This medicine specifically hampers the Ablesontyrosine kinase (ABL). The mentioned rational cancer drug therapy approaches have been alsostudied for other types of cancer. Future personalized therapy approaches to effective cancer carecould be extended to improve the quality of life of human being, early detection and clinicalmanagement of the cancer, and its investigations. Besides it will change the current concepts aboutcancer therapies and also the molecular mechanisms of cancer through a systems medicineapproach.کلیدواژه ها
مقالات مرتبط جدید
اطلاعات بیشتر در مورد COI
COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.
کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.